A Prodrug Strategy to Reposition Atovaquone as a Long-Acting Injectable for Malaria Chemoprotection
A. K. Gupta, A. M. Eliasen, W. Andahazy, F. Zhou, K. Henson, V. Chi, A. K. Woods, S. B. Joseph, K. L. Kuhen, J. Wisler, H. Ramachandruni, J. Duffy, J. N. Burrows, E. Vadas, A. Slade, , A. K. Chatterjee
This paper develops three prodrug formulations of atovaquone for long-acting injectable malaria chemoprotection, showing two maintain therapeutic plasma levels for over 70 and 30 days in monkeys.
bioRxiv · Feb 8, 2024 · PreprintPharmacology & Toxicology